Genetic and epigenetic factors determining NAFLD risk

Background: Hepatic steatosis is a common chronic liver disease that can progress into more severe stages of NAFLD or promote the development of life-threatening secondary diseases for some of those affected. These include the liver itself (nonalcoholic steatohepatitis or NASH; fibrosis and cirrhosi...

Full description

Bibliographic Details
Main Authors: Wenke Jonas, Annette Schürmann
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Molecular Metabolism
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221287782030185X
id doaj-082e0fa38aff4c7c97960d7849486fe0
record_format Article
spelling doaj-082e0fa38aff4c7c97960d7849486fe02021-07-23T04:48:46ZengElsevierMolecular Metabolism2212-87782021-08-0150101111Genetic and epigenetic factors determining NAFLD riskWenke Jonas0Annette Schürmann1Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, D-14558, Nuthetal, Germany; German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, D-85764, München-Neuherberg, GermanyDepartment of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, D-14558, Nuthetal, Germany; German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, D-85764, München-Neuherberg, Germany; University of Potsdam, Institute of Nutritional Sciences, Arthur-Scheunert-Allee 114-116, D-14558, Nuthetal, Germany; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Cottbus-Senftenberg, The Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany; Corresponding author. German Institute of Human Nutrition Potsdam-Rehbruecke, Department of Experimental Diabetology, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany. Fax: +49 (0) 33200 88 2334.Background: Hepatic steatosis is a common chronic liver disease that can progress into more severe stages of NAFLD or promote the development of life-threatening secondary diseases for some of those affected. These include the liver itself (nonalcoholic steatohepatitis or NASH; fibrosis and cirrhosis, and hepatocellular carcinoma) or other organs such as the vessels and the heart (cardiovascular disease) or the islets of Langerhans (type 2 diabetes). In addition to elevated caloric intake and a sedentary lifestyle, genetic and epigenetic predisposition contribute to the development of NAFLD and the secondary diseases. Scope of review: We present data from genome-wide association studies (GWAS) and functional studies in rodents which describe polymorphisms identified in genes relevant for the disease as well as changes caused by altered DNA methylation and gene regulation via specific miRNAs. The review also provides information on the current status of the use of genetic and epigenetic factors as risk markers. Major conclusion: With our overview we provide an insight into the genetic and epigenetic landscape of NAFLD and argue about the applicability of currently defined risk scores for risk stratification and conclude that further efforts are needed to make the scores more usable and meaningful.http://www.sciencedirect.com/science/article/pii/S221287782030185XNAFLDGenetic variantsEpigeneticsRisk score
collection DOAJ
language English
format Article
sources DOAJ
author Wenke Jonas
Annette Schürmann
spellingShingle Wenke Jonas
Annette Schürmann
Genetic and epigenetic factors determining NAFLD risk
Molecular Metabolism
NAFLD
Genetic variants
Epigenetics
Risk score
author_facet Wenke Jonas
Annette Schürmann
author_sort Wenke Jonas
title Genetic and epigenetic factors determining NAFLD risk
title_short Genetic and epigenetic factors determining NAFLD risk
title_full Genetic and epigenetic factors determining NAFLD risk
title_fullStr Genetic and epigenetic factors determining NAFLD risk
title_full_unstemmed Genetic and epigenetic factors determining NAFLD risk
title_sort genetic and epigenetic factors determining nafld risk
publisher Elsevier
series Molecular Metabolism
issn 2212-8778
publishDate 2021-08-01
description Background: Hepatic steatosis is a common chronic liver disease that can progress into more severe stages of NAFLD or promote the development of life-threatening secondary diseases for some of those affected. These include the liver itself (nonalcoholic steatohepatitis or NASH; fibrosis and cirrhosis, and hepatocellular carcinoma) or other organs such as the vessels and the heart (cardiovascular disease) or the islets of Langerhans (type 2 diabetes). In addition to elevated caloric intake and a sedentary lifestyle, genetic and epigenetic predisposition contribute to the development of NAFLD and the secondary diseases. Scope of review: We present data from genome-wide association studies (GWAS) and functional studies in rodents which describe polymorphisms identified in genes relevant for the disease as well as changes caused by altered DNA methylation and gene regulation via specific miRNAs. The review also provides information on the current status of the use of genetic and epigenetic factors as risk markers. Major conclusion: With our overview we provide an insight into the genetic and epigenetic landscape of NAFLD and argue about the applicability of currently defined risk scores for risk stratification and conclude that further efforts are needed to make the scores more usable and meaningful.
topic NAFLD
Genetic variants
Epigenetics
Risk score
url http://www.sciencedirect.com/science/article/pii/S221287782030185X
work_keys_str_mv AT wenkejonas geneticandepigeneticfactorsdeterminingnafldrisk
AT annetteschurmann geneticandepigeneticfactorsdeterminingnafldrisk
_version_ 1721290583999250432